摘要
目的 :观察重度心衰患者应用卡维地洛的临床疗效。方法 :132例心功能NYHA分级Ⅲ、Ⅳ级的心力衰竭患者随机分为卡维地洛组及常规治疗组 ,前组除常规治疗外加用卡维地洛 6 .2 5mg/d ,渐加至 5 0～ 10 0mg/d或最大耐受量。观察治疗 3个月后心率及应用彩色多普勒超声心动图方法观察每搏量 (SV )、心输出量 (CO)、射血分数 (EF)及左室舒张末期内径(EDD)的变化。结果 :卡维地洛组治疗重度心衰有效率显著高于常规治疗组。卡维地洛组用药前后非常显著地降低了HR、EDD ,提高了SV、EF、CO(P <0 .0 1) ,而常规治疗组仅HR及SV改善明显 (P <0 .0 5 )。卡维地洛组HR较常规治疗组有显著降低 (P <0 .0 5 ) ,而其它指标均较常规治疗组有非常显著改善 (P <0 .0 1)。结论 :卡维地洛能显著改善心脏功能 ,副作用小 。
Objective: To evaluate the clinical efficacy of carvedilol in sever heart failure. Methods:132 patients with sever CHF of NYHA grade Ⅲ、Ⅳ were divided randomly into group carvedilol and group routine therapy. The patients in group carvedilol were given treatment as same as group routine therapy and carvedilol as well ,beginning with carvedilol 6.25mg /d , until 50-100mg/d or reach the maximum endurable dosage . Observe the changes of HR, SV, CO, EF and CO of each groups three months later. Results: Group carvedilol has a higher efficiency in the treatment of sever CHF(92.4% vs 62.1%),with HR、EDD reduced significantly and SV、EF、CO increased significantly(P<0.01). While in group routine therapy, only HR and SV changed significantly(P<0.05).Compared: with group routine therapy ,HR were reduced significantly(P<0.05) and EDD,SV, EF, CO were increased significantly in group carvedilol(P<0.01).Conclusion: Carvedilol can improve the function of heart with less side effect, so it can be used in the treatment of sever heart failure safely.
